Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jorge Cortes

Showing results (581-590 of 713) with videos related to

Pageof 72
Sort By:
The Lancet. Oncology|February 24, 2012
Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 studyHagop Kantarjian, Deborah Thomas, Jeffrey Jorgensen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 5, 2011
Multivariable model for time to first treatment in patients with chronic lymphocytic leukemiaWilliam G Wierda, Susan O'Brien, Xuemei Wang, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 18, 2021
Clinical Outcomes of Patients With Chronic Myeloid Leukemia With Concurrent Core Binding Factor Rearrangement and Philadelphia ChromosomeKiyomi Morita, Elias Jabbour, Farhad Ravandi, et al.
American Journal of Hematology|December 9, 2017
Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignanciesCourtney D DiNardo, Caitlin R Rausch, Christopher Benton, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 15, 2020
Salvage Therapy Outcomes in a Historical Cohort of Patients With Relapsed or Refractory Acute Myeloid LeukemiaFarhad Ravandi, Sherry Pierce, Guillermo Garcia-Manero, et al.
Cancer|September 26, 2019
Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemiaKiran Naqvi, Elias Jabbour, Jeffrey Skinner, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 31, 2014
A prognostic model of therapy-related myelodysplastic syndrome for predicting survival and transformation to acute myeloid leukemiaAlfonso Quintás-Cardama, Naval Daver, Hawk Kim, et al.
Cancer|July 28, 2016
TP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomesTapan M Kadia, Preetesh Jain, Farhad Ravandi, et al.
Cancer|August 19, 2007
The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cellsMichael W N Deininger, Jorge Cortes, Ron Paquette, et al.
American Journal of Hematology|September 28, 2016
Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemiasBrittany Knick Ragon, Hagop Kantarjian, Elias Jabbour, et al.
Pageof 72

Showing results (581-590 of 713) with videos related to

Sort By:
Pageof 72
The Lancet. Oncology|February 24, 2012
Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 studyHagop Kantarjian, Deborah Thomas, Jeffrey Jorgensen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 5, 2011
Multivariable model for time to first treatment in patients with chronic lymphocytic leukemiaWilliam G Wierda, Susan O'Brien, Xuemei Wang, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 18, 2021
Clinical Outcomes of Patients With Chronic Myeloid Leukemia With Concurrent Core Binding Factor Rearrangement and Philadelphia ChromosomeKiyomi Morita, Elias Jabbour, Farhad Ravandi, et al.
American Journal of Hematology|December 9, 2017
Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignanciesCourtney D DiNardo, Caitlin R Rausch, Christopher Benton, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 15, 2020
Salvage Therapy Outcomes in a Historical Cohort of Patients With Relapsed or Refractory Acute Myeloid LeukemiaFarhad Ravandi, Sherry Pierce, Guillermo Garcia-Manero, et al.
Cancer|September 26, 2019
Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemiaKiran Naqvi, Elias Jabbour, Jeffrey Skinner, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 31, 2014
A prognostic model of therapy-related myelodysplastic syndrome for predicting survival and transformation to acute myeloid leukemiaAlfonso Quintás-Cardama, Naval Daver, Hawk Kim, et al.
Cancer|July 28, 2016
TP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomesTapan M Kadia, Preetesh Jain, Farhad Ravandi, et al.
Cancer|August 19, 2007
The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cellsMichael W N Deininger, Jorge Cortes, Ron Paquette, et al.
American Journal of Hematology|September 28, 2016
Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemiasBrittany Knick Ragon, Hagop Kantarjian, Elias Jabbour, et al.
Pageof 72